Gilead Sciences GILD Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 315.4%+7.1pp | 314.4%+8.5pp | 313.8%+10.2pp | 311.2%+4.8pp | 308.4%-1.7pp | |
| Operating margin | 132.9%+86.4pp | 126.6%+103pp | 98.3%+52.5pp | 65.2%-8.0pp | 46.5%-48.4pp | |
| Net margin | 109.6%+83.0pp | 99.4%+91.7pp | 72.2%+45.3pp | 44.7%-3.1pp | 26.7%-37.5pp | |
| EBITDA margin | 138%+84.0pp | 131.8%+96.4pp | 103.6%+39.5pp | 70.5%-27.1pp | 54%-69.0pp | |
| Free cash flow margin | 130.5%+2.3pp | 130.3%+7.6pp | 134.1%+19.8pp | 135.9%+26.3pp | 128.2%+10.8pp | |
| Returns | ||||||
| Return on equity | 157.5%+117pp | 146.8%+136pp | 108.6%+74.4pp | 68.7%+8.0pp | 40.7%-41.0pp | |
| Return on assets | 56.7%+43.3pp | 50.9%+47.3pp | 37.3%+25.4pp | 23.1%+2.1pp | 13.4%-14.6pp | |
| Return on invested capital | 86.7%+58.7pp | 82.3%+71.7pp | 63%+40.5pp | 41.6%+4.5pp | 27.9%-20.1pp | |
| Efficiency | ||||||
| Asset turnover | 2.1×+0.1× | 2.1×+0.1× | 2×+0.2× | 2×+0.2× | 1.9×+0.2× | |
| Inventory turnover | 12.1×-4.0× | 12.9×-4.2× | 13.7×-4.3× | 15.1×-2.9× | 16.1×-1.5× | |
| Liquidity | ||||||
| Current ratio | 6.3×+0.9× | 5.7×+0.6× | 5.7×+0.8× | 5.5×+0.6× | 5.4×+0.5× | |
| Quick ratio | 5.4×+0.6× | 4.9×+0.4× | 5×+0.6× | 4.9×+0.4× | 4.8×+0.4× | |
| Cash ratio | 2.5×+0.3× | 2.3×+0.5× | 2.5×+0.9× | 2.4×+0.7× | 2.2×+0.4× | |
| Leverage | ||||||
| Debt-to-equity | 4.5×-0.8× | 4.9×-0.5× | 5.1×0.0× | 5.2×+0.3× | 5.3×+0.4× | |
| Debt-to-assets | 1.7×-0.1× | 1.7×0.0× | 1.8×+0.1× | 1.8×+0.1× | 1.8×+0.1× | |
| Net debt / EBITDA | 7.1×-24.4× | 7.7×-28.4× | 14.4×-15.2× | 28×+11.7× | 31.5×+19.2× | |
| Interest coverage | 38.4×+24.9× | 36.5×+29.7× | 28.4×+15.2× | 18.9×-2.4× | 13.5×-14.4× | |
| Per Share | ||||||
| Book value per share | $69.70+16.2% | $66.16+12.5% | $63.48+3.1% | $61.03-5.5% | $59.97-10.2% | |
| Valuation | ||||||
| Market capitalization | $596.35B+34.1% | $563.05B+42.1% | $525.88B+37.6% | $492.53B+32.7% | $444.66B+16.5% | |
| Enterprise value | $666.28B+28.7% | $635.46B+34.4% | $597.65B+29.7% | $564.9B+25.3% | $517.81B+12.4% | |
| Price / earnings | 74.8×-1,098× | 79.4×-1,259× | 301.4×-815× | 1,112.8×+809× | 1,172.8×+933× | |
| Price / sales | 20.3×+4.7× | 19.4×+5.3× | 18.2×+4.4× | 17.2×+3.6× | 15.6×+1.7× | |
| Price / book | 27.2×+3.7× | 27.2×+5.7× | 26.4×+6.5× | 25.7×+7.2× | 23.6×+5.2× | |
| EV / EBITDA | 66.3×-149× | 67.1×-166× | 115.5×-65.0× | 203.5×+114× | 215.4×+145× | |
| EV / sales | 22.7×+4.5× | 21.9×+5.1× | 20.7×+4.0× | 19.7×+3.3× | 18.2×+1.4× | |
| Free cash flow yield | 25.8%-7.3pp | 26.9%-7.8pp | 29.7%-3.4pp | 32.1%-0.4pp | 33.1%-0.6pp | |
| Earnings yield | 21.5%+15.5pp | 20.5%+18.2pp | 15.3%+7.8pp | 9.5%-4.1pp | 6%-12.1pp | |
| Dividend yield | 10.8%-3.6pp | 11.3%-4.5pp | 12.1%-4.1pp | 12.9%-3.6pp | 14.5%-1.5pp | |
| PEG ratio | 0.4×— | 0.1×— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Gilead Sciences's profit margins?
- Gilead Sciences (GILD) runs a 79.4% gross margin and a 34.9% operating margin, with a 31.0% net margin.
- Where do Gilead Sciences's ratios come from?
- Every ratio is computed from Gilead Sciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
